1.Wong, VCW, et al. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HbeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Double-blind randomised placebo-controlled study. Lancet 1984; i: 921–926.
2.Beasley, RP, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983; ii: 1099–1102.
3.Beasley, RP, et al. HBIG prophylaxis for perinatal HBV infections – final report of the Taiwan trial. Developments in Biological Standardization 1983; 54: 363–375.
4.Leung, NW. Patterns of viral hepatitis in Hong Kong. British Journal of Hospital Medicine 1997; 58: 166–169.
5.Stevens, CE, et al. Vertical transmission of hepatitis B antigen in Taiwan. New England Journal of Medicine 1975; 292: 771–774.
6.Yeoh, EK. Hepatitis B vaccination – Who should be vaccinated? [Editorial]. Journal of the Hong Kong Medical Association 1987; 39: 208–209.
7.Assad, S, Francis, A. Over a decade of experience with a yeast recombinant hepatitis B vaccine. Vaccine 1999; 18: 57–67.
8.Nair, PV, et al. Efficacy of hepatitis B immune globulin in prevention of perinatal transmission of the hepatitis B virus. Gastroenterology 1984; 87: 293–298.
9.Lee, PI, et al. A follow-up study of combined vaccination with plasma-derived and recombinant hepatitis B vaccines in infants. Vaccine 1995; 13: 1685–1689.
10.Lee, C, et al. Hepatitis B prophylaxis for newborns of hepatitis B surface antigen-positive mothers Cochrane Database of Systematic Reviews 2004. Issue 2. Art. No. CD004790.
11.Kwan, LC, Ho, YY, Lee, SS. The declining HbsAg carriage rate in pregnant women in Hong Kong. Epidemiology and Infection 1997; 119: 281–283.
12.Lok, ASF. Hepatitis B vaccination in Hong Kong. Journal of Gastroenterology and Hepatology 1993: 8: S27–S29.
14.The Scientific Working Group on Viral Hepatitis Prevention. Recommendations on hepatitis B Vaccination Regimens in Hong Kong – Consensus of the scientific working group on viral hepatitis prevention. Hong Kong: Department of Health, 1998, p. 9.
15.Lee, SS. Hepatitis B vaccination programme in Hong Kong. Public Health & Epidemiology Bulletin 1993; 2: 9–12.
16.Leung, CW. Proceedings of state of Asian children – immunization. Hong Kong Journal of Paediatrics (New Series) 1999; 4: 9–62.
17.Yeoh, EK, Young, B, Chan, YY. Determinants of immunogenicity and efficacy of hepatitis B vaccine in infants. In: Hollinger, FB, Lemon, SM, Margolis, HS, eds. Viral Hepatitis and Liver Disease. Baltimore, Maryland: Williams & Wilkins, 1991.
18.Gabbuti, A, et al. Long-term immunogenicity of hepatitis B vaccination in a cohort of Italian healthy adolescents. Vaccine 2007; 25: 3129–3132.
19.Hammitt, LL, et al. Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years. Vaccine 2007; 25: 6958–6964.
20.Poovorawan, Y, et al. Long-term hepatitis B vaccine in infants born to hepatitis B e antigen positive mothers. Archives of Diseases in Childhood (Fetal and Neonatal Edition) 1997; 77: F47–51.
21.Poovorawan, Y, et al. Long term efficacy of hepatitis B vaccine in infants born to hepatitis B e antigen-positive mothers. Pediatric Infectious Disease Journal 1992; 11: 816–821.
22.Alfaleh, FZ, et al. Long-term protection of hepatitis B vaccine 18 years after vaccination. Journal of Infection 2008; 57: 404–409.
23.Liao, SS, et al. Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children. Vaccine 1999; 17: 2661–2666.
24.Ni, YH, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Annals of Internal Medicine 2001; 135: 796–800.
25.Chan, OK, et al. Correlation between maternal hepatitis B surface antigen carrier status with social, medical and family factors in an endemic area – have we overlooked something? Infection 2011; 39: 419–426.
26.Zanetti, AR, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005; 366: 1379–1384.
27.Lu, CY, et al. Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology 2004; 40: 1415–1420.
28.McMahon, BJ, et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Annals of Internal Medicine 2005; 142; 333–341.
29.Su, FH, et al. Waning-off effect of serum hepatitis B surface antibody amongst Taiwanese university students: 18 years post-implementation of Taiwan's national hepatitis B vaccination programme. Journal of Viral Hepatitis 2008; 15: 14–19.
30.Ni, YH, et al. Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies. Gastroenterology 2007; 132: 1287–1293.
31.Lin, DB, et al. Immune status in preschool children born after mass hepatitis B vaccination program in Taiwan. Vaccine 1998; 16: 1683–1687.
32.Gold, Y, et al. Decreased immune response to hepatitis B eight years after routine vaccination in Israel. Acta Paediatrica 2003; 92: 1158–1162.
33.Miñana, JS, et al. Hepatitis B vaccine immunoresponsiveness in adolescents: a revaccination proposal after primary vaccination. Vaccine 1996; 14: 103–106.
34.Bialek, SR, et al. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth. A 15-year follow-up study. Pediatric Infectious Disease Journal 2008; 27: 881–885.
35.Department of Health, Hong Kong. Rubella in Hong Kong Public Health and Epidemiology Bulletin 1995; 4: 17–20.
36.Chuang, SK, et al. Mass measles immunization campaign: experience in the Hong Kong Special Administration Region of China. Bulletin of the World Health Organization 2002; 80: 585–591.
37.Lao, TT, et al. Chronic hepatitis B virus infection and rubella susceptibility in pregnant women. Journal of Viral Hepatitis 2010; 17: 737–741.
38.Su, FH, et al. Seroprevalence of hepatitis-B infection amongst Taiwanese university students 18 years following the commencement of a national hepatitis-B vaccination program. Journal of Medical Virology 2007; 79: 138–143.
39.Samandari, T, et al. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy. Pediatrics 2007; 120: e373–381.
40.Chien, YC, et al. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched. Epidemiology Review 2006; 28: 126–135.
41.Chang, MH, et al. for the Taiwan Children HCC Study Group. Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems. Clinical Cancer Research 2005; 11: 7953–7957.
42.Villarejos, VM, et al. A. Role of saliva, urine and feces in the transmission of type B hepatitis. New England Journal of Medicine 1974; 291: 1375–1378.
43.Scott, RM, et al. Experimental transmission of hepatitis B virus by semen and saliva. Journal of Infectious Diseases 1980; 142: 67–71.
44.Inaba, N, et al. Sexual transmission of hepatitis B surface antigen infection of husband by HbsAg carrier-state wives. British Journal of Venereal Diseases 1979; 55: 366–368.
45.Heng, BH, et al. Prevalence of hepatitis B virus (HBV) infection in Singapore men with sexually transmitted diseases and HIV infection: role of sexual transmission in a city state with intermediate HBV endemicity. Journal of Epidemiology and Community Health 1995; 49: 309–313.
46.Ko, YC, et al. Female to male transmission of hepatitis B virus between Chinese Spouses. Journal of Medical Virology 1989; 27: 142–144.
47.Wang, CW, et al. Long-term follow-up of hepatitis B surface antibody levels in subjects receiving universal hepatitis B vaccination in infancy in an area of hyperendemicity: Correlation between radioimmunoassay and enzyme immunoassay. Clinical and Diagnostic Laboratory Immunology 2005; 12: 1442–1447.
48.John, TJ, Cooksley, G, on behalf of the Steering Committee for the Prevention and Control of Infectious Diseases in Asia. Review. Hepatitis B vaccine boosters: Is there a clinical need in high endemicity populations? Journal of Gastroenterology and Hepatology 2005; 20: 5–10.
49.Wang, LY, Lin, HH. Ethnicity, substance use, and response to booster hepatitis B vaccination in anti-HBs-seronegative adolescents who had received primary infantile vaccination. Journal of Hepatology 2007; 46: 1018–1025.